BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase. 2023

Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

α-Glucosidase as a carbohydrate-hydrolase enzyme is a crucial therapeutic target for type 2 diabetes. In this work, benzo[d]imidazole-amide containing 1,2,3-triazole-N-arylacetamide derivatives 8a-n were synthesized and evaluated for their inhibitory activity against α-glucosidase. In vitro α-glucosidase inhibition assay demonstrated that more than half of the title compounds with IC50 values in the range of 49.0-668.5 μM were more potent than standard inhibitor acarbose (IC50 = 750.0 µM). The most promising inhibitor was N-2-methylphenylacetamid derivative 8c. Kinetic study revealed that compound 8c (Ki = 40.0 µM) is a competitive inhibitor against α-glucosidase. Significantly, molecular docking and molecular dynamics studies on the most potent compound showed that this compound with a proper binding energy interacted with important amino acids of the α-glucosidase active site. Study on cytotoxicity of the most potent compounds 8c, 8e, and 8g demonstrated that these compounds did not show cytotoxic activity against the cancer and normal cell lines MCF-7 and HDF, respectively. Furthermore, the ADMET study predicted that compound 8c is likely to be orally active and non-cytotoxic.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007700 Kinetics The rate dynamics in chemical or physical systems.
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000520 alpha-Glucosidases Enzymes that catalyze the exohydrolysis of 1,4-alpha-glucosidic linkages with release of alpha-glucose. Deficiency of alpha-1,4-glucosidase may cause GLYCOGEN STORAGE DISEASE TYPE II. Acid Maltase,Lysosomal alpha-Glucosidase,Maltase,Maltases,Maltase-Glucoamylase,Neutral Maltase,Neutral alpha-Glucosidase,alpha-Glucosidase,Lysosomal alpha Glucosidase,Maltase Glucoamylase,Neutral alpha Glucosidase,alpha Glucosidase,alpha Glucosidases,alpha-Glucosidase, Lysosomal,alpha-Glucosidase, Neutral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
December 2019, Bioorganic & medicinal chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents.
November 2022, BMC chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
November 2019, Bioorganic chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study.
March 2019, Bioorganic chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design and synthesis of 4,5-diphenyl-imidazol-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic and docking studies.
May 2021, Molecular diversity,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides as potential anti-diabetic agents.
June 2023, Scientific reports,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Synthesis and biological evaluation of new benzimidazole-1,2,3-triazole hybrids as potential α-glucosidase inhibitors.
January 2020, Bioorganic chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Indole-carbohydrazide linked phenoxy-1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro α-glucosidase inhibition, and computational studies.
June 2023, BMC chemistry,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
New 4-phenylpiperazine-carbodithioate-N-phenylacetamide hybrids: Synthesis, in vitro and in silico evaluations against cholinesterase and α-glucosidase enzymes.
May 2022, Archiv der Pharmazie,
Faeze Yousefnejad, and Mahyar Mohammadi-Moghadam-Goozali, and Mohammad Hosein Sayahi, and Mohammad Halimi, and Ali Moazzam, and Maryam Mohammadi-Khanaposhtani, and Somayeh Mojtabavi, and Mehdi Asadi, and Mohammad Ali Faramarzi, and Bagher Larijani, and Massoud Amanlou, and Mohammad Mahdavi
Design, synthesis, and in silico studies of quinoline-based-benzo[d]imidazole bearing different acetamide derivatives as potent α-glucosidase inhibitors.
August 2022, Scientific reports,
Copied contents to your clipboard!